This study investigated the role of P2Y purinergic receptor 12 (P2Y12) in osteoclast function. ADP-mediated stimulation of P2Y12 on osteoclasts enhanced adhesion and resorptive activity; these effects were not seen in P2y12−/− osteoclasts. P2y12−/− mice had decreased osteoclast resorptive activity and were partially protected from bone loss that occurred as a result of age, arthritis, osteoporosis or tumour growth. Moreover, wild-type mice treated with the clinical P2Y12 inhibitor clopidogrel were protected from bone loss, suggesting that P2Y12 inhibition is a potential target for this disorder.
ORIGINAL RESEARCH PAPER
Su, X. et al. The ADP receptor P2RY12 regulates osteoclast function and pathologic bone remodeling. J. Clin. Invest. 122, 3579–3592 (2012)
Rights and permissions
About this article
Cite this article
Harrison, C. Clopidogrel prevents bone loss. Nat Rev Drug Discov 11, 832 (2012). https://doi.org/10.1038/nrd3882
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3882